Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 5, Issue 15
August 10 2021
Issue Cover

Table of Contents

CLINICAL GUIDELINE

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America
Ignacio Neumann,Ariel Izcovich,Ricardo Aguilar,Guillermo León Basantes,Patricia Casais,Cecilia C. Colorio,María Cecilia Guillermo Esposito,Pedro P. García Lázaro,Luis A. Meillon-García,Jaime Pereira,Suely Meireles Rezende,Juan Carlos Serrano,Mario L. Tejerina Valle,Felipe Vera,Lorena Karzulovic,Gabriel Rada,Holger Schünemann
View Articletitled, ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America
Supplemental data
Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context
Ignacio Neumann,Ariel Izcovich,Kendall E. Alexander,Jenny Castano,Robert Plovnick,Robert Kunkle,Yuan Zhang,Ricardo Aguilar,Guillermo León Basantes,Patricia Casais,Cecilia C. Colorio,María Cecilia Guillermo Esposito,Pedro P. García Lázaro,Jaime Pereira,Luis A. Meillon-García,Suely Meireles Rezende,Juan Carlos Serrano,Mario L. Tejerina Valle,Holger Schünemann
View Articletitled, Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context

EXCEPTIONAL CASE REPORT

Effective anti-BCMA retreatment in multiple myeloma
Clinical Trials & Observations
Nicolas Gazeau,David Beauvais,Ibrahim Yakoub-Agha,Suman Mitra,Timothy B. Campbell,Thierry Facon,Salomon Manier
View Articletitled, Effective anti-BCMA retreatment in multiple myeloma

STIMULUS REPORT

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Peter G. Miller,Adam S. Sperling,Elliott J. Brea,Mark B. Leick,Geoffrey G. Fell,Max Jan,Satyen H. Gohil,Yu-Tzu Tai,Nikhil C. Munshi,Catherine J. Wu,Donna S. Neuberg,Marcela V. Maus,Caron Jacobson,Christopher J. Gibson,Benjamin L. Ebert
View Articletitled, Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma
Austin B. Bigley,Shanae Spade,Nadia H. Agha,Sujit Biswas,Suni Tang,Muhammad H. Malik,Lu Dai,Shalaleh Masoumi,Bonell Patiño-Escobar,Martina Hale,Guy DiPierro,Ronald Martell,Byron Hann,Nina Shah,Arun P. Wiita,Xinli Liu
View Articletitled, FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma
Supplemental data

LYMPHOID NEOPLASIA

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma
Clinical Trials & Observations
Jonathan C. Strefford,Malgorzata Nowicka,Chantal E. Hargreaves,Cathy Burton,Andrew Davies,Rosalind Ganderton,Wolfgang Hiddemann,Chisako Iriyama,Wolfram Klapper,Kate V. Latham,Maurizio Martelli,Farheen Mir,Helen Parker,Kathleen N. Potter,Matthew J. J. Rose-Zerilli,Laurie H. Sehn,Marek Trněný,Umberto Vitolo,Christopher R. Bolen,Christian Klein,Andrea Knapp,Mikkel Z. Oestergaard,Mark S. Cragg
View Articletitled, Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma
Supplemental data
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment
Clinical Trials & Observations
Malgorzata Nowicka,Laura K. Hilton,Margaret Ashton-Key,Chantal E. Hargreaves,Chern Lee,Russell Foxall,Matthew J. Carter,Stephen A. Beers,Kathleen N. Potter,Christopher R. Bolen,Christian Klein,Andrea Knapp,Farheen Mir,Matthew Rose-Zerilli,Cathy Burton,Wolfram Klapper,David W. Scott,Laurie H. Sehn,Umberto Vitolo,Maurizio Martelli,Marek Trneny,Christopher K. Rushton,Graham W. Slack,Pedro Farinha,Jonathan C. Strefford,Mikkel Z. Oestergaard,Ryan D. Morin,Mark S. Cragg
View Articletitled, Prognostic significance of <em>FCGR2B</em> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment
Supplemental data
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study
Clinical Trials & Observations
Mirian Brink,Xaver U. Kahle,Joost S. P. Vermaat,Josee M. Zijlstra,Martine Chamuleau,Marie José Kersten,Müjde Durmaz,Wouter J. Plattel,Pieternella J. Lugtenburg,Wendy Stevens,Rogier Mous,Elisabeth G. E. de Vries,Marjolein W. M. van der Poel,Prashant V. Nannan Panday,Gerwin Huls,Tom van Meerten,Marcel Nijland
View Articletitled, Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Identification of the transcription factor MAZ as a regulator of erythropoiesis
Darya Deen,Falk Butter,Deborah E. Daniels,Ivan Ferrer-Vicens,Daniel C. J. Ferguson,Michelle L. Holland,Vasiliki Samara,Jacqueline A. Sloane-Stanley,Helena Ayyub,Matthias Mann,Jan Frayne,David Garrick,Douglas Vernimmen
View Articletitled, Identification of the transcription factor MAZ as a regulator of erythropoiesis
Supplemental data

THROMBOSIS AND HEMOSTASIS

Bleeding diathesis in mice lacking JAK2 in platelets
Nathan Eaton,Saravanan Subramaniam,Marie L. Schulte,Caleb Drew,David Jakab,Sandra L. Haberichter,Hartmut Weiler,Hervé Falet
View Articletitled, Bleeding diathesis in mice lacking JAK2 in platelets
Supplemental data
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
Luciano Baronciani,Ian Peake,Reinhard Schneppenheim,Anne Goodeve,Minoo Ahmadinejad,Zahra Badiee,Mohammad-Reza Baghaipour,Olga Benitez,Imre Bodó,Ulrich Budde,Andrea Cairo,Giancarlo Castaman,Peyman Eshghi,Jenny Goudemand,Wolf Hassenpflug,Hamid Hoorfar,Mehran Karimi,Bijan Keikhaei,Riitta Lassila,Frank W. G. Leebeek,Maria Fernanda Lopez Fernandez,Pier Mannuccio Mannucci,Renato Marino,Nikolas Nikšić,Florian Oyen,Cristina Santoro,Andreas Tiede,Gholamreza Toogeh,Alberto Tosetto,Marc Trossaert,Eva M. K. Zetterberg,Jeroen Eikenboom,Augusto B. Federici,Flora Peyvandi
View Articletitled, Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
Supplemental data

RESEARCH LETTER

Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP
Clinical Trials & Observations
Sophie Bernard,Herve Ghesquieres,Rene-Olivier Casasnovas,Samuel Griolet,Maria Gomes da Silva,Pierre Feugier,Franck Morschhauser,Judith Trotman,Loic Renaud,Richard Greil,Alejandro Martín García-Sancho,Sebastian Grosicki,Koen van Eygen,Christiane Copie-Bergman,Corinne Haioun,Catherine Thieblemont
View Articletitled, Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP
Supplemental data
  • Cover Image

    Cover Image

    issue cover

    Potential mechanisms of resistance to anti-BCMA immunotherapies. Three mechanisms (antigen loss, BCMA shedding by soluble BCMA, and the secretion of antidrug antibodies) are target dependent. Two mechanisms of resistance (T-cell exhaustion and the emergence of a nonpermissive microenvironment) are T cell dependent. See the article by Gazeau et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals